- Home
- OMI vs ERAS Comparison
OMI vs ERAS Comparison
Compare OMI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMI
- ERAS
- Stock Information
- Founded
- OMI 1882
- ERAS 2018
- Country
- OMI United States
- ERAS United States
- Employees
- OMI N/A
- ERAS N/A
- Industry
- OMI Medical Specialities
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- OMI Health Care
- ERAS Health Care
- Exchange
- OMI Nasdaq
- ERAS Nasdaq
- Market Cap
- OMI 415.6M
- ERAS 439.7M
- IPO Year
- OMI N/A
- ERAS 2021
- Fundamental
- Price
- OMI $4.59
- ERAS $2.40
- Analyst Decision
- OMI Hold
- ERAS Buy
- Analyst Count
- OMI 7
- ERAS 6
- Target Price
- OMI $7.96
- ERAS $3.83
- AVG Volume (30 Days)
- OMI 2.8M
- ERAS 2.5M
- Earning Date
- OMI 10-31-2025
- ERAS 11-11-2025
- Dividend Yield
- OMI N/A
- ERAS N/A
- EPS Growth
- OMI N/A
- ERAS N/A
- EPS
- OMI N/A
- ERAS N/A
- Revenue
- OMI $10,758,440,000.00
- ERAS N/A
- Revenue This Year
- OMI N/A
- ERAS N/A
- Revenue Next Year
- OMI N/A
- ERAS N/A
- P/E Ratio
- OMI N/A
- ERAS N/A
- Revenue Growth
- OMI 64.35
- ERAS N/A
- 52 Week Low
- OMI $4.34
- ERAS $1.01
- 52 Week High
- OMI $15.54
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- OMI 38.67
- ERAS 65.30
- Support Level
- OMI $4.34
- ERAS $2.36
- Resistance Level
- OMI $5.19
- ERAS $2.76
- Average True Range (ATR)
- OMI 0.28
- ERAS 0.23
- MACD
- OMI 0.00
- ERAS 0.02
- Stochastic Oscillator
- OMI 18.14
- ERAS 63.80
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.